N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 5,012 shares at $41.54 ($208K) on 2024-02-07, disclosed to the SEC on 2024-02-08.
Open-market sale of $208k CERE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.54 | 2,506 | $104K | 50.0% |
| 2 | $41.54 | 2,506 | $104K | 50.0% |
| Total | $41.54 avg | 5,012 | $208K | 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |